Reply to: Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a western population

Eva Doorakkers¹, Jesper Lagergren^{1

2}, Lars Engstrand^{3

4}, Nele Brusselaers^{3

4

5}

Affiliations

¹ Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
² Division of Cancer Studies, King's College London, London, UK.
³ Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
⁴ Sciencefor Life Laboratory (SciLifeLab), Stockholm, Sweden.
⁵ Ghent University, Ghent, Belgium.

Comment

Eva Doorakkers et al. Gut. 2020 Jun.

. 2020 Jun;69(6):1149-1150.

doi: 10.1136/gutjnl-2019-319000. Epub 2019 May 21.

Eva Doorakkers¹, Jesper Lagergren^{1

2}, Lars Engstrand^{3

4}, Nele Brusselaers^{3

4

5}

¹ Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
² Division of Cancer Studies, King's College London, London, UK.
³ Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
⁴ Sciencefor Life Laboratory (SciLifeLab), Stockholm, Sweden.
⁵ Ghent University, Ghent, Belgium.

No abstract available

Keywords: gastric cancer; helicobacter pylori.

Conflict of interest statement

Competing interests: None declared.

Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population.
Doorakkers E, Lagergren J, Engstrand L, Brusselaers N. Doorakkers E, et al. Gut. 2018 Dec;67(12):2092-2096. doi: 10.1136/gutjnl-2017-315363. Epub 2018 Jan 30. Gut. 2018. PMID: 29382776